PA
EIGR

Perceptive Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Perceptive Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,054
Closed -$8.99M – 192
2015
Q1 		$8.99M Buy
+1,054
New +$9.21M 0.7% 35

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors's EIGR Position: Q1 2022 in Review

Perceptive Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2022, closing a stake of 4,663 shares — an estimated $726K sold.

Perceptive Advisors first reported a position in EIGR in Q1 2016 and held it in 24 quarters. The position peaked at $2.2M in Q4 2017. 94 funds tracked by Wall St. Rank hold EIGR as of Q1 2022.

  • Perceptive Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Perceptive Advisors sold 4,663 Eiger BioPharmaceuticals, Inc. shares in Q1 2022, an estimated $726K.
  • Perceptive Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2016 and held it in 24 quarters.
  • Perceptive Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $2.2M in Q4 2017.
  • 94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.